Skip to content
TrialScanner

NCT04421560

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/Phase 2RecruitingMRKCollaborator

Registry record

Lead sponsor
Dana-Farber Cancer Institute
Conditions
Primary Central Nervous System Lymphoma; Recurrent Cancer; Refractory Cancer; Relapsed Cancer
Primary completion
Dec 5, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04421560 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04421560: Pembrolizumab, Ibrutinib and... | TrialScanner